SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 459.75 |
| Enterprise Value ($M) | 309.74 |
| Book Value ($M) | 232.11 |
| Book Value / Share | 4.38 |
| Price / Book | 1.98 |
| NCAV ($M) | 192.41 |
| NCAV / Share | 3.63 |
| Price / NCAV | 2.39 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.44 |
| Return on Assets (ROA) | -0.46 |
| Return on Equity (ROE) | -0.66 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 5.09 |
| Current Ratio | 5.09 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 253.61 |
| Assets | 293.32 |
| Liabilities | 61.21 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Lynx1 Capital Management LP | 9.90 | 75.43 | |
| 13G/A | Redmile Group, LLC | 9.00 | 79.53 | |
| 13G | Baker Bros. Advisors Lp | 8.30 | ||
| 13G/A | Vanguard Group Inc | 5.24 | 0.00 | |
| 13D/A | Skorpios Trust | 16.90 | -17.87 | |
| 13G | BlackRock, Inc. | 10.40 | ||
| 13G/A | Cowen Financial Products LLC | 8.30 | 198.19 | |
| 13G/A | Rtw Investments, Lp | 9.30 | 6.72 | |
| 13G/A | Fmr Llc | 0.01 | -99.84 | |
| 13G/A | Morgan Stanley | 7.50 | 37.18 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 644,076 | 1,232,613 | 52.25 | |
| 133,603 | 709,146 | 18.84 | |
| 165,885 | 665,871 | 24.91 | |
| 380,485 | 1,105,006 | 34.43 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| SPRO – Spero Therapeutics, Inc. | SRPT – Sarepta Therapeutics, Inc. |
| SRRK – Scholar Rock Holding Corporation | STTK – Shattuck Labs, Inc. |
| SVRA – Savara Inc. |
Financial data and stock pages provided by
Fintel.io